Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy

Laryngoscope. 1996 Jul;106(7):884-8. doi: 10.1097/00005537-199607000-00019.


The purpose of this study was to determine the overexpression of both epidermal growth factor receptor (EGFR) and transforming growth factor-alpha (TGF-alpha) (a ligand of EGFR) in early laryngeal squamous cell carcinoma. In addition, we attempted to evaluate the prognostic values of our findings. Expression of EGFR and TGF-alpha in tumor tissue was examined immunohistochemically in 68 patients who had been treated with radiotherapy for early laryngeal cancer. Overexpression of the two factors was noted in 42.6% and 55.9%, respectively. No significant differences due to age, tumor size, and location or grade of cancer tissues were seen. Higher survival rates, found in patients with EGFR (-) and TGF-alpha (-) tumors as compared with those with EGFR (+) and TGF-alpha (+) (97.4%, 100% and 86.2%, 86.8%, respectively), were not statistically significant. The recurrence rates were similar between EGFR (+) and EGFR (-) (37.9% and 35.9%, respectively). However, the recurrence rate in patients with TGF-alpha (+) was significantly higher (57.9%) than in those with TGF-alpha (-) (10%; P<.01). Therefore overexpression of TGF-alpha may be an important indicator for recurrence in patients with early laryngeal squamous cell carcinoma treated by irradiation.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / chemistry
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / radiotherapy*
  • ErbB Receptors / analysis*
  • Female
  • Humans
  • Immunohistochemistry
  • Laryngeal Neoplasms / chemistry
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Prognosis
  • Survival Rate
  • Transforming Growth Factor alpha / analysis*


  • Transforming Growth Factor alpha
  • ErbB Receptors